MESA LABORATORIES INC /CO Form 8-K April 07, 2014 UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

### **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

# April 4, 2014

Date of Report (Date of earliest event reported)

# MESA LABORATORIES, INC.

(Exact name of registrant as specified in its charter)

Commission File Number: 0-11740

COLORADO 84-0872291
(State or other jurisdiction of incorporation) Identification No.)

### 12100 WEST SIXTH AVENUE,

80228

<u>LAKEWOOD, COLORADO</u> (Zip Code)

(Address of principal executive offices)

Registrant's telephone number, including area code: (303) 987-8000

(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
_  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
_  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
_  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
_  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

# **ITEM 8.01 OTHER EVENTS**

On April 4, 2014, Mesa Laboratories, Inc. (the "Company") entered into and closed a share purchase agreement whereby it acquired all of the common stock of Amilabo SAS ("Amilabo"). Amilabo is located near Lyon, France and is a distributor of the Company's biological indicator products.

# ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(d) Exhibits:

99.1 Press release dated April 4, 2014.

### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Mesa Laboratories, Inc.

(Registrant)

DATE: April 7, 2014

/s/ John J. Sullivan

BY: John J. Sullivan,

President and Chief Executive Officer